Edwards Lifesciences Corporation (EW)
Automate Your Wheel Strategy on EW
With Tiblio's Option Bot, you can configure your own wheel strategy including EW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EW
- Rev/Share 9.685
- Book/Share 18.069
- PB 4.3936
- Debt/Equity 0.0666
- CurrentRatio 4.6823
- ROIC 0.1063
- MktCap 46339803000.0
- FreeCF/Share 1.0356
- PFCF 76.2293
- PE 11.1708
- Debt/Assets 0.0521
- DivYield 0
- ROE 0.4125
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | EW | BTIG Research | Neutral | Buy | -- | $100 | July 29, 2025 |
| Upgrade | EW | Piper Sandler | Neutral | Overweight | -- | $80 | April 24, 2025 |
| Upgrade | EW | Stifel | Hold | Buy | $75 | $90 | Jan. 30, 2025 |
| Downgrade | EW | Wolfe Research | Peer Perform | Underperform | -- | $60 | Jan. 16, 2025 |
| Upgrade | EW | BofA Securities | Neutral | Buy | -- | -- | Dec. 16, 2024 |
| Resumed | EW | Morgan Stanley | -- | Equal Weight | -- | $70 | Oct. 11, 2024 |
| Downgrade | EW | Jefferies | Buy | Hold | $85 | $70 | Sept. 18, 2024 |
News
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Lifesciences.
Read More
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve
Published: August 06, 2025 by: Reuters
Sentiment: Negative
The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition.
Read More
Edwards Lifesciences Comments on FTC's Action to Block Proposed Acquisition of JenaValve
Published: August 06, 2025 by: Business Wire
Sentiment: Neutral
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of.
Read More
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027
Published: August 06, 2025 by: Benzinga
Sentiment: Neutral
Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.
Read More
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Read More
Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Read More
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative
EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.
Read More
Smart Money Going in Senior Health: Key Stocks in Elderly Care
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Read More
Edwards Lifesciences: With A Heart Beating Strong And Steady
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages.
Read More
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Read More
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.
Read More
Trade Tracker: Bill Baruch buys Edwards Lifesciences
Published: May 19, 2025 by: CNBC Television
Sentiment: Positive
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
Read More
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
Read More
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible lat.
Read More
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens
Published: April 24, 2025 by: Benzinga
Sentiment: Positive
Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.
Read More
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Read More
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew …
Read More
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
About Edwards Lifesciences Corporation (EW)
- IPO Date 2000-03-27
- Website https://www.edwards.com
- Industry Medical - Devices
- CEO Bernard J. Zovighian
- Employees 15800